CSL Limited announces tender offer to acquire Vifor Pharma Ltd
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR
Global biotechnology leader CSL Limited (ASX: CSL; USOTC:CSLLY) and Vifor Pharma Ltd (SIX:VIFN; ISIN:CH0364749348), a global specialty pharmaceutical company with leadership in iron deficiency, nephrology & cardio-renal therapies, today announced that they have entered into a definitive agreement for CSL to acquire Vifor Pharma for an aggregate equity value for Vifor Pharma of US$ 11.7 / CHF 10.9 billion.
CSL has offered to acquire Vifor Pharma in an all-cash tender offer of US$179.25 (CHF 167) per share, payable in U.S. dollars.1 The offer assumes a dividend of CHF 2 expected to be declared at the AGM of 26 April, consistent with past practice.
The tender offer represents an implied premium of approximately 61% to the unaffected closing price of Vifor Pharma on 1 December 2021 and a 47% premium to Vifor Pharma’s unaffected 1-month VWAP as of 1 December 2021.2
Patinex AG, Vifor Pharma’s largest shareholder holding 23.2% has agreed to tender its shares into the offer.
The Transaction remains subject to the conditions and further terms including:
- Minimum acceptance rate of 80% of all Vifor Pharma shares on a fully diluted basis; and
- further customary offer conditions, including regulatory approvals.
The tender is currently expected to commence around 18 January 2022 and the transaction is expected to complete around mid-2022.
The Board of Directors of Vifor Pharma considers that the proposed transaction respects the interests of all stakeholders and is unanimously recommending the offer to shareholders. There is committed financing for the deal and a strong commitment to pursue regulatory clearances.
“Vifor Pharma's strategy has been to focus towards continuing being a market leader in iron deficiency, nephrology and cardio-renal therapies.” Jacques Theurillat, Chairman of the Board of Directors Vifor Pharma Group commented. “The offer provides an excellent strategic opportunity for Vifor Pharma to optimize future market opportunities from a position of strength and to create substantial value for all stakeholders.”
The transaction will enable Vifor Pharma to leverage CSL’s global reach, balance sheet and capabilities to bring more products to patients within its key categories. The transaction also enables Vifor Pharma to accelerate growth in cardiovascular-metabolic, renal and transplant.
Centerview Partners UK LLP is acting as exclusive financial advisor to Vifor Pharma on the transaction.
IFBC have been retained as Fairness Opinion providers by the Vifor Pharma Board of Directors.
About Vifor Pharma Group
Vifor Pharma Group is a global pharmaceuticals company. It aims to become the global leader in iron deficiency, nephrology and cardio-renal therapies. The company is a partner of choice for pharmaceuticals and innovative patient-focused solutions. Vifor Pharma Group strives to help patients around the world with severe and chronic diseases lead better, healthier lives. The company develops, manufactures and markets pharmaceutical products for precision patient care. Vifor Pharma Group holds a leading position in all its core business activities and consists of the following companies: Vifor Pharma and Vifor Fresenius Medical Care Renal Pharma (a joint company with Fresenius Medical Care). Vifor Pharma Group is headquartered in Switzerland, and listed on the Swiss Stock Exchange (SIX Swiss Exchange, VIFN, ISIN: CH0364749348).
For more information, please visit viforpharma.com.
CSL (ASX: CSL; USOTC:CSLLY) is a leading global biotechnology company with a dynamic portfolio of life-saving medicines, including those that treat hemophilia and immune deficiencies, as well as vaccines to prevent influenza. Since our start in 1916, we have been driven by our promise to save lives using the latest technologies. Today, CSL — including our two businesses, CSL Behring and Seqirus- provides life-saving products to more than 100 countries and employs more than 25,000 people. Our unique combination of commercial strength, R&D focus and operational excellence enables us to identify, develop and deliver innovations so our patients can live life to the fullest. For more information visit csl.com.
Important Additional Information
The tender offer described herein has not yet commenced. This release is for informational purposes only and does not constitute, or form part of, any offer or invitation to sell or issue, or any solicitation of any offer, to purchase or subscribe for any registered shares or other equity securities in Vifor Pharma Ltd., nor shall it form the basis of, or be relied on in connection with, any contract therefor. This release is not part of the offer documentation relating to the tender offer. Main terms and conditions of the tender offer have been published in today's Pre-Announcement of the tender offer, and full details including terms and conditions will be published in the tender offer prospectus. Shareholders of Vifor Pharma Ltd. are urged to read the tender offer documents, which are or will be available at www.CSLtransaction.com.
Certain Offer Restrictions
Reference is made to the Pre-Announcement of the tender offer published today for full offer restrictions.
1 At USD to CHF FX rate of 0.932.
2 Based on the last closing price of Vifor Pharma prior to public speculation regarding a potential transaction.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
Global Head Corporate Communications
+41 79 957 96 73
Edwin van der Geest
Dynamics Group AG
+41 79 330 55 22
Head of Investor Relations
+41 58 851 66 90
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Specifica Validates Best-in-Class Status for in vitro Antibody Discovery Platform in Two Key Peer Reviewed Publications29.1.2022 02:00:00 EET | Press release
Specifica, a privately held antibody engineering company focused on innovative in vitro antibody library and discovery tools, announced the publication of two peer-reviewed articles describing its Generation 3 Antibody Discovery Platform1,2. Antibodies are the fastest growing class of therapeutics, representing nine of the top twenty best-selling drugs3. The global antibody therapy market is projected to grow from $178.50 billion in 2021 to $451.89 billion in 2028 at a CAGR of 14.1%4. Traditionally, therapeutic antibodies have been generated by harvesting immune responses, either from in-bred or transgenic mice, or from immune human subjects. Although there has been a long-standing interest in using in vitro antibody library approaches that avoid the use of animals, there have been two main concerns with antibodies from in vitro libraries: binding affinities tend to be lower, and poor developability characteristics are common, complicating their development as successful drugs. As desc
ADVA Optical Networking SE: Acorn HoldCo, Inc. reaches minimum acceptance threshold for its public exchange offer to all shareholders of ADVA Optical Networking SE29.1.2022 01:45:00 EET | Press release
ADTRAN, Inc. today announced that by the end of the acceptance period on January 26, 2022, 24:00 hours (local time Frankfurt am Main), the voluntary public takeover offer of Acorn HoldCo, Inc. (“Bidder”) to all shareholders of ADVA Optical Networking SE (“ADVA“) has been accepted for more than 60% of all ADVA shares entitled to voting rights and existing as of October 31, 2021. The minimum acceptance threshold has therefore been reached. The final result as at the end of the acceptance period is expected to be published on January 31, 2022. ADTRAN, Inc. and ADVA have thus reached yet another important milestone for the merger of the two companies and have come closer to their goal of creating a leading company in the field of optical transmission technology for enterprise, access and wide-area networks. The consummation of the public exchange offer continues to be subject to closing conditions not yet fulfilled, especially foreign direct investment approval in Germany. ADVA shareholder
causaLens Raises $45m Series A to Scale Human-centered AI That Understands Cause-and-effect28.1.2022 17:46:00 EET | Press release
causaLens, the London deep tech company delivering the future of AI, has raised a $45m Series A round. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220126005888/en/ The causaLens co-founders, Dr. Maksim Sipos, CTO, on the left, and Dr. Darko Matovski, CEO, on the right. (Photo: Business Wire) causaLens is the pioneer of Causal AI - the only AI technology quantifying cause-and-effect relationships to reason alongside humans in a manner that is trustworthy, explainable, and fair. Causal AI represents a giant leap ahead of current correlation-based AI technologies, which blindly extrapolate historical data and are unable to ask counterfactual questions — the ‘what ifs’ at the core of human imagination and creativity. causaLens’s no-code platform delivers far more accurate and reliable results, and allows humans and machines to work together for the first time. It is trusted by decision makers across finance, industry, technol
Monrol Signing Agreement to License its GMP Grade Lu-177 n.c.a Production Technology to Curium28.1.2022 15:47:00 EET | Press release
Eczacıbaşı-Monrol Nuclear Products Co. (Monrol) has today announced it has signed an agreement with Curium Netherlands B.V (Curium) to license its GMP grade medical radioisotope, no-carrier-added 177Lu (n.c.a. 177Lu) cutting-edge production technology LuMagic®. This agreement will enable transfer of relevant equipment and supply from Monrol to Curium. Monrol is one of the few producers of Lutetium-177 n.c.a worldwide, having uninterrupted worldwide supply capabilities. Monrol Lu-177 n.c.a production process is an exclusive processing technology having cleaner and safer production method with stable isotope enrichment capability. Curium planning to manufacture the product Lu-177 n.c.a in its Petten production facility, Netherlands. This licence is offering significant opportunities both for Curium; one of the world’s largest nuclear medicine companies and Monrol; a company which develops, manufactures, and distributes world-class radiopharmaceutical products, radioisotopes to improve qu
CHMP issues positive opinion to expand Jardiance (empagliflozin) indication based on unprecedented benefit in adult heart failure patients with preserved ejection fraction28.1.2022 15:26:00 EET | Press release
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted a positive opinion recommending Jardiance® (empagliflozin) for the treatment of adults with symptomatic chronic heart failure, Boehringer Ingelheim and Eli Lilly and Company announced today.1 Empagliflozin was previously approved for the treatment of adults with symptomatic chronic heart failure with reduced ejection fraction (HFrEF).4 If approved, the positive opinion would expand this indication to be applicable for adults across the full spectrum of left ventricular ejection fraction (LVEF), including preserved ejection fraction (HFpEF). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220127005861/en/ “For the very first time, we now have a treatment that will improve clinical results across the full spectrum of heart failure patients – regardless of ejection fraction,” said Professor Stefan Anker, Heart Failure Car
Schlumberger DELFI Digital Platform Selected by Northern Lights JV for CO2 Project28.1.2022 15:00:00 EET | Press release
Schlumberger will deploy the DELFI* cognitive E&P environment on the Norwegian CO2 project by the Northern Lights Joint Venture (NL), to streamline subsurface workflows and longer-term modeling and surveillance of CO2 sequestration. NL was established to develop the world’s first open-source CO2 transport and storage infrastructure, providing accelerated decarbonization opportunities for European industries, with an ambition to store up to 5 million tonnes of CO2 per year based on market demand. For CO2 transportation and storage, Schlumberger digital solutions are used for subsurface characterization and dynamic reservoir simulation, which are key to understanding storage site capacity and the potential for injecting and containing fluids. They are also used for development planning, operations, appraisals, and monitoring purposes. “Northern Lights has recognized the huge potential of Schlumberger’s digital technology to fast-track decision making and de-risk CO2 transportation and st
Pixis Appoints Neel Pandya as the CEO for Europe Business, in Addition to APAC28.1.2022 14:28:00 EET | Press release
Pixis (formerly known as Pyxis One), a leading provider of contextual codeless AI infrastructure for complete marketing optimization, today appointed Neel Pandya as the Chief Executive Officer of its operations in Europe, in addition to his responsibilities of leading the APAC business. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220128005166/en/ Neel Pandya joined Pixis as the CEO of APAC in its Bengaluru office after exiting L'Oréal. (Photo: Business Wire) Neel joined Pixis in its Bengaluru office in July 2021 as the CEO of APAC, bringing immense change and progress to the way Pixis operates, and greatly streamlining expansions in the APAC region. Under his leadership, Pixis witnessed a 185% growth in revenue in the APAC region, with India independently recording a 150% of growth. Over the last 7 months, in addition to greatly stabilizing customer churn Neel has also been instrumental in adding close to 30 new enterpris
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom